

### REMARKS

In response to the restriction requirement set forth in the Office Action mailed March 21, 2006 in the above-application:

Applicants hereby elect the invention of Group I, method claims 10-15 and 25-27, without traverse, for examination at this time.

In response to the election of species requirement, Applicants elect clopidogrel as the ADP receptor antagonist and ridogrel as the thromboxane A<sub>2</sub> receptor antagonist. This election is made without traverse. Pending Claims 10-15 and 25-27 read on the elected species, of which 10, 14, 15, 25 and 26 are generic.

In view of the above election, Applicants have canceled nonelected claims 1-9, 16-24 and 28 without prejudice to the filing of any potential divisional, continuation, or continuation-in-part application. Consideration of the elected claims is now requested.

Respectfully Submitted,

OMEROS CORPORATION



Marcia S. Kelbon  
Vice President, Patent & General Counsel  
Registration No. 34,358  
Direct Dial No. 206.676.5020

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

4-14-06  
Date

StM-  
Stephanie Jansen

MSK:sj